All lobbying filings

AVENUE SOLUTIONS

AVENUE SOLUTIONS filed a Q4 report for EDWARDS LIFESCIENCES LLC on January 20, 2026, reporting $50,000 in lobbying income.

Lobbying for EDWARDS LIFESCIENCES LLC · Patient-focused innovations for structural heart disease and critical care monitoring

All filings by AVENUE SOLUTIONS · Everything EDWARDS LIFESCIENCES LLC has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Expiring healthcare extenders

Bills named in this filing 2

H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.